Skip to main navigation

Investors
News
- News Releases
- News and Mentions
Presentations & Events
- Presentations
- Events
Stock Performance
- Stock Information
- Analyst Coverage
Financials & Filings
- SEC Filings
- Quarterly Results
Corporate Governance
Resources

News Releases

Year

Sep 10 / 24

Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease

Sep 03 / 24

Belite Bio to Participate in Three Upcoming Investor Conferences

Sep 01 / 24

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Aug 09 / 24

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aug 08 / 24

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 05 / 24

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

Jul 08 / 24

Belite Bio to Present at the JonesHealthcare Seaside Summit

Jun 18 / 24

Belite Bio Receives Approval to Initiate a Second Stargardt Disease Clinical Trial in the United Kingdom

Jun 12 / 24

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 9 of 27

Belite Bio™ Inc
12750 High Bluff Drive Suite 475,
San Diego CA, 92130 USA

Join our mailing list.

Sign up to receive important updates and news from Belite Bio